CM
REGN icon

Castleark Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Castleark Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-2,500
Closed -$1.27M – 400
2015
Q2 		$1.27M Buy
+2,500
New +$1.22M 0.03% 298
2014
Q4 		– Sell
-30,410
Closed -$9.13M – 386
2014
Q3 		$9.13M Buy
+30,410
New +$10.2M 0.26% 78
2014
Q2 		– Sell
-30,410
Closed -$9.13M – 335
2014
Q1 		$9.13M Buy
+30,410
New +$9.37M 0.26% 78

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Castleark Management's REGN Position: Q3 2015 in Review

Castleark Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2015, closing a stake of 2,500 shares — an estimated $1.27M sold.

Castleark Management first reported a position in REGN in Q1 2014 and held it in 3 quarters. The position peaked at $9.13M in Q3 2014. 563 funds tracked by Wall St. Rank hold REGN as of Q3 2015.

  • Castleark Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Castleark Management sold 2,500 Regeneron Pharmaceuticals shares in Q3 2015, an estimated $1.27M.
  • Castleark Management first reported a position in Regeneron Pharmaceuticals in Q1 2014 and held it in 3 quarters.
  • Castleark Management's Regeneron Pharmaceuticals position peaked at $9.13M in Q3 2014.
  • 563 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2015.

Based on Castleark Management's 13F filing for Q3 2015, filed 17 Nov 2015.